Clinical Trials Logo

Substance-Related Disorders clinical trials

View clinical trials related to Substance-Related Disorders.

Filter by:

NCT ID: NCT04976855 Not yet recruiting - Healthy Volunteer Clinical Trials

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

The primary objectives for the study are: - Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers. - Part III: Assess the safety and tolerability of repeated doses of INDV-2000 administered alone and with SUBOXONE sublingual (SL) film in an opioid use disorder (OUD) treatment seeking population.

NCT ID: NCT04974645 Not yet recruiting - Clinical trials for Substance Use Disorders

Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use

Start date: July 29, 2021
Phase: Phase 2
Study type: Interventional

This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to an education-only control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.

NCT ID: NCT04969081 Not yet recruiting - Clinical trials for Substance-related Disorders

Impact of Work Activity on SUD Outcomes

Start date: January 3, 2022
Phase: N/A
Study type: Interventional

To date, there are no studies of the therapeutic effects of varied work-focused programs in Veterans undergoing outpatient substance use disorder (SUD) treatment. The investigators propose a randomized clinical trial to test the effects of work-focused programs on improving sobriety and other clinical outcomes in Veterans early in the course of recovery from SUD. Veterans will be randomized to either receive or not receive referral for work-focused therapeutic programs. Primary aim is to examine effects of work-focused programs on sobriety outcomes, namely sobriety and global functioning. Secondary aim is to examine effects of work-focused programs on psychiatric symptoms, self esteem/efficacy, and quality of life.

NCT ID: NCT04965961 Active, not recruiting - Sports Drug Abuse Clinical Trials

The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females

Start date: August 28, 2019
Phase: N/A
Study type: Interventional

Recombinant human erythropoietin (rHuEPO) regimen enhances maximal oxygen consumption (VO2max), but the effect of micro-doses on maximal and submaximal performance is not clear and detection of micro-doses is difficult with current methods. This study investigated whether micro-doses of rHuEPO enhances maximal and endurance performance in males and females.

NCT ID: NCT04965740 Recruiting - Depression Clinical Trials

Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids

Start date: June 4, 2021
Study type: Observational

The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy programs. These preliminary data will help to inform and guide the development of a larger patient-oriented study and the design of a clinical program geared towards enhancing therapy treatments for first responders and military personnel.

NCT ID: NCT04959461 Not yet recruiting - Clinical trials for Substance-Related Disorders

Preventing Impaired Driving Among Adolescents

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The primary goal of this project is to evaluate the efficacy of webCHAT, a single-session web-intervention, on reducing impaired driving among adolescents receiving behind-the-wheel training at driver education programs.

NCT ID: NCT04958798 Not yet recruiting - Opioid-use Disorder Clinical Trials

Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This is a formative research study to test a culturally-centered, program-level implementation intervention to increase the use of medications for opioid use disorder in four healthcare and addiction specialty treatment sites serving American Indian and Alaska Native communities.

NCT ID: NCT04953338 Active, not recruiting - Anxiety Disorders Clinical Trials

Mental Health Associations With Vitiligo

Start date: June 18, 2021
Study type: Observational

This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with vitiligo compared to controls and to evaluate whether the relative risks may vary by different ethnicity.

NCT ID: NCT04948307 Recruiting - Opioid-use Disorder Clinical Trials

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Start date: June 30, 2021
Phase: N/A
Study type: Interventional

This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC) background therapy compared to SL BUP/NAL alone to change opioid use patterns in subjects with OUD. Approximately 400 subjects will be randomized. The study will include a screening visit and a randomization visit, followed by 24 weeks of study treatment. Subjects will be scheduled for evaluation visits, which will include a UDS and a self report of drug use, weekly during the first four weeks of treatment, then every other week from weeks 5 through 12, then monthly through week 25. Subjects will also return to the site for only a urine drug screen (UDS) and a self-report of drug use each week between the evaluation visits. The primary objective of the study is to determine whether the combination of sublingual (SL) buprenorphine/naloxone (BUP/NAL) standard of care (SOC) background therapy and the digital therapeutic OXD01 is superior to SL BUP/NAL alone to reduce opioid use.

NCT ID: NCT04939727 Not yet recruiting - Opioid Use Clinical Trials

Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0

Start date: June 28, 2021
Phase: N/A
Study type: Interventional

This study integrates the Mental Health Research Network (MHRN) suicide risk models into Opioid Wizard, an electronic health record (EHR) clinical decision support (CDS) to identify and treat patients at high risk of opioid use disorder (OUD)/overdose or diagnosed with OUD, to alert primary care clinicians (PCCs) to patients at elevated risk for suicide and guide them through structured suicide risk assessment. In both intervention and control clinics, suicide risk scores will be calculated for all Opioid Wizard-eligible patients and relevant EHR data to inform analyses will be archived. In intervention clinics, Opioid Wizard will alert PCCs to Opioid Wizard-eligible patients who are at increased risk of suicide and coach them through use of the Columbia Suicide Severity Risk Scale (CSSRS), a structured tool in the EHR that will help PCCs assess immediate suicide risk. Based on the resulting CSSRS score, Opioid Wizard will provide EHR links for risk-based referrals and follow-up recommendations, including care as usual, routine or emergent referral to behavioral health, or transportation to the emergency department (ED) for further assessment. Primary outcome measures include completion of CSSRS assessments for at-risk patients and patient engagement in outpatient mental health care.